{"disease":{"id":"hyperparathyroidism","name":"Hyperparathyroidism","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":5},"drugs":{"marketed":[{"drug_id":"etelcalcetide","indication_name":"Secondary Hyperparathyroidism in CKD on Hemodialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parsabiv","generic_name":"ETELCALCETIDE","company_name":"Kai Pharms Inc","drug_phase":"marketed","molecular_target":"CaSR","drug_class":"Calcium-sensing Receptor Agonist","quality_score":70,"revenue":null,"mechanism":"Etelcalcetide enhances calcium-sensing receptor activation, reducing PTH secretion."},{"drug_id":"calcitriol-capsules","indication_name":"Secondary Hyperparathyroidism in Predialysis Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calcitriol capsules","company_name":"Indonesia University","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin D3 Analog [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"upacicalcet","indication_name":"Secondary hyperparathyroidism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Upasita","generic_name":"UPACICALCET","company_name":"SANWA KAGAKU KENKYUSHO Co., Ltd.","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"evocalcet","indication_name":"Hypercalcemia in primary hyperparathyroidism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orkedia","generic_name":"EVOCALCET","company_name":"Kyowa Hakko Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"evocalcet","indication_name":"Secondary hyperparathyroidism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orkedia","generic_name":"EVOCALCET","company_name":"Kyowa Hakko Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"paricalcitol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zemplar","generic_name":"PARICALCITOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D2 Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Zemplar works by activating the Vitamin D3 receptor, mimicking the natural effects of Vitamin D to regulate calcium levels and bone health."},{"drug_id":"cinacalcet","indication_name":"Hypercalcemia due to Primary Hyperparathyroidism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sensipar","generic_name":"CINACALCET","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"Calcium-sensing Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood."},{"drug_id":"cinacalcet","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sensipar","generic_name":"CINACALCET","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"Calcium-sensing Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hyperparathyroidism.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"calciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"alfacalcidol","indication_name":"Hyperparathyroidism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alfarol","generic_name":"ALFACALCIDOL","company_name":"","drug_phase":"discontinued","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"alfacalcidol","quality_score":null,"revenue":null,"mechanism":"Alfarol works by activating vitamin D receptors in the body, which helps regulate calcium levels."},{"drug_id":"etelcalcetide","indication_name":"Secondary hyperparathyroidism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parsabiv","generic_name":"ETELCALCETIDE","company_name":"Kai Pharms Inc","drug_phase":"marketed","molecular_target":"CaSR","drug_class":"Calcium-sensing Receptor Agonist","quality_score":70,"revenue":null,"mechanism":"Etelcalcetide enhances calcium-sensing receptor activation, reducing PTH secretion."},{"drug_id":"doxercalciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hectorol","generic_name":"DOXERCALCIFEROL","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D2 Analog [EPC]","quality_score":70,"revenue":null,"mechanism":"Hectorol works by activating the Vitamin D receptor, which helps regulate calcium levels in the body."},{"drug_id":"calcitriol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcijex","generic_name":"CALCITRIOL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D3 Analog [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"zemplar","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zemplar","company_name":"Danderyd Hospital","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rocaltrol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rocaltrol","company_name":"Shandong University","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"alphacalcidol","indication_name":"Hyperparathyroidism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Alphacalcidol","company_name":"University of Ioannina","drug_phase":"phase_2","molecular_target":"Sodium-dependent noradrenaline transporter, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT00345839","title":"E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3883,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04969926","title":"Natural History Study of Parathyroid Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT00001277","title":"Studies of Elevated Parathyroid Activity","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1553,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":true},{"nct_id":"NCT06797934","title":"Establishment of a Registry of Patients With Parathyroid Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03747029","title":"Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study","phase":"","overall_status":"COMPLETED","enrollment_count":1038,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria di Modena","has_results":false},{"nct_id":"NCT03203668","title":"18F-fluorocholine PET/CT Imaging in Hyperparathyroidism","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"University Medical Centre Ljubljana","has_results":false},{"nct_id":"NCT02102204","title":"Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":902,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01785875","title":"Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":891,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05997810","title":"Parathyroid Tumor Clonal Status","phase":"","overall_status":"RECRUITING","enrollment_count":839,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03194087","title":"the Study on Prognostic for Hemodialysis Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":827,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT06523582","title":"Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universidad Nacional Autonoma de Mexico","has_results":false},{"nct_id":"NCT03123406","title":"Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Kyowa Kirin China Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06450431","title":"Parathyroid Assessment of Symptoms French Version","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT01896232","title":"Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":683,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03299244","title":"Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":637,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01788046","title":"Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01785849","title":"Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":508,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07379463","title":"Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Tianjin Medical University","has_results":false},{"nct_id":"NCT06434961","title":"The Trial of SHR6508 in Secondary Hyperparathyroidism","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":498,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03137316","title":"Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy","phase":"","overall_status":"COMPLETED","enrollment_count":437,"lead_sponsor_name":"Benha University","has_results":false},{"nct_id":"NCT07122401","title":"Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":424,"lead_sponsor_name":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT06852144","title":"PET-TC in Thyroid Evaluation","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":418,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT05836220","title":"Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":412,"lead_sponsor_name":"Pathalys Pharma","has_results":false},{"nct_id":"NCT03822507","title":"Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":404,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT05469087","title":"Cohort Primary Hyperparathyroidism","phase":"","overall_status":"RECRUITING","enrollment_count":403,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03973450","title":"Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Neuromed IRCCS","has_results":false},{"nct_id":"NCT05549154","title":"A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":372,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT05832931","title":"Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"Pathalys Pharma","has_results":false},{"nct_id":"NCT06711874","title":"Abnormally High Parathyroid Hormone Levels Worsens Outcomes in Vitamin D Depleted Critical Care Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":320,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT00803712","title":"20070360 Incident Dialysis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01181531","title":"Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03039439","title":"Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06976177","title":"Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04844164","title":"Vitamin D Metabolism in Patients With Endocrine Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":261,"lead_sponsor_name":"Endocrinology Research Centre, Moscow","has_results":false},{"nct_id":"NCT03052075","title":"Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04740502","title":"Surgical Outcomes in Patients With Primary Hyperparathyroidism and Unclear Preoperative Localisation Studies","phase":"NA","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"University of Cagliari","has_results":false},{"nct_id":"NCT04013100","title":"Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas","phase":"","overall_status":"TERMINATED","enrollment_count":235,"lead_sponsor_name":"IHU Strasbourg","has_results":false},{"nct_id":"NCT03091140","title":"Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Aristotle University Of Thessaloniki","has_results":false},{"nct_id":"NCT04922892","title":"Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"The Second Hospital of Nanjing Medical University","has_results":false},{"nct_id":"NCT07444723","title":"Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":193,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT07010380","title":"Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder)","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Bo Wang,MD","has_results":false},{"nct_id":"NCT01409798","title":"The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry","phase":"","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"University of Nebraska","has_results":false},{"nct_id":"NCT04305561","title":"Preoperative Localization Strategies in Primary Hyperparathyroidism","phase":"NA","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT05022641","title":"Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT04299425","title":"Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":true},{"nct_id":"NCT01932970","title":"Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03626948","title":"SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"Sanwa Kagaku Kenkyusho Co., Ltd.","has_results":false},{"nct_id":"NCT03801980","title":"Phase 3 Study of SK-1403","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Sanwa Kagaku Kenkyusho Co., Ltd.","has_results":false},{"nct_id":"NCT03968510","title":"Swalqol in Primary Hyperparathyroidism","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Uşak University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}